ArQule, Inc. (ARQL) Release: Phase 2 Study Results for Tivantinib in Combination with Cetuximab and Irinotecan for Colorectal Cancer Presented at American Society of Clinical Oncology 2013
6/3/2013 7:09:37 AM
More...
|
ArQule, Inc. (ARQL) to Present at Jefferies and Co. 2013 Global Healthcare Conference
5/30/2013 7:12:05 AM
More...
|
ArQule, Inc. (ARQL) Reports First Quarter 2013 Financial Results
5/8/2013 7:57:10 AM
More...
|
ArQule, Inc. (ARQL) to Report First Quarter 2013 Financial Results on May 8, 2013
5/1/2013 7:32:51 AM
More...
|
ArQule, Inc. (ARQL) to Present at Needham 12th Annual Healthcare Conference
4/23/2013 6:59:35 AM
More...
|
ArQule, Inc. (ARQL) Regains Rights to AKT Inhibitor From Daiichi Sankyo, Inc. (4568.t)
4/1/2013 7:05:04 AM
More...
|
ArQule, Inc. (ARQL) Reports Fiscal 2012 Year End and Fourth Quarter Results
3/15/2013 8:19:18 AM
More...
|
ArQule, Inc. (ARQL) Reports Fiscal 2012 Year End and Fourth Quarter Results
3/14/2013 6:29:58 AM
More...
|
ArQule, Inc. (ARQL) to Report Fiscal 2012 Financial Results on March 14, 2013
3/7/2013 6:38:09 AM
More...
|
ArQule, Inc. (ARQL) to Present at Cowen and Company 33rd Annual Health Care Conference
2/27/2013 6:42:42 AM
More...
|
|